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Background: Although irregularities in human zona pellucida (ZP) morphology are well described, there is scant
literature on the clinical significance of ZP dysmorphology. We, therefore, designed a retrospective cohort trial of ZP
dysmorphology to assess the clinical significance of ZP dysmorphology and its affect on IVF outcome. Over the same
time period a random sample of 77 cycles of 77 subjects with all normal oocyte morphology were selected as controls.
Methods: Between July 2006 and December 2010, all fresh non-donor cases performed at a university hospital IVF
center were assessed for ZP dysmorphology. ZP dysmorphology included extracytoplasmic abnormalities (dark ZP
and large perivitelline space) and oocyte shape (oval or irregularly shaped ZP). 136 IVF cycles from 119 subjects were
identified where a majority of oocytes displayed ZP dysmorphology. Over the same time period a random sample of
77 cycles of 77 subjects with all normal oocyte morphology were selected as controls. IVF prognostic and outcome
parameters were compared between the patients with dysmorphic and normal oocytes.
Results: 136/1710 (8.0%) cycles of fresh non-donor IVF displayed predominant ZP dysmorphology. Dysmorphic and
normal oocytes showed no difference in the oocyte quality predictors such as FSH (6.03+/−2.5 vs. 6.8+/−2.3 IU/L), or AMH
(2.5+/−2.0 vs. 2.30+/−1.5 ng/ml levels). ZP dysmorphology was associated with markedly diminished clinical pregnancy
rates (44% vs. 70%; RR:0.62 [0.48, 0.80]; p = 0.0002), implantation rates (.17 vs. .36; IRR: 0.48 [0.34, 0.68]; p < 0.0001) and live
birth rates as compared to non dysmorphic oocytes (29% vs. 52%; RR:0.55 [0.39, 0.79]; p = 0.001).
Conclusions: ZP dysmorphology is associated with markedly diminished pregnancy and implantation rates in IVF.
The poorer outcome appears to be independent of the usual markers of ovarian reserve.
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Irregularities in human zona pellucida (ZP) morphology
have been described in the literature. ZP Dysmorphology
has an incidence of 2-5% of all oocytes [1,2]. The ZP
has an important role in oocyte fertilization and when
thickening is present it may prevent implantation. It is
essential for sperm binding and preventing polyspermy.
It may have a protective role prior to hatching and
protecting embryos from mechanical stress prior to
implantation.* Correspondence: Maytag99@gmail.com
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article, unless otherwise stated.The Atlas of Human Gametes lists ZP darkening, focal
thickening, bilayering, irregular shape, as well as debris
within the zona or periviteline space as ZP dysmorphology
that may benefit from ICSI. Yet, there's scant literature
on the clinical significance of ZP dysmorphology. IVF
laboratory morphological assessment of retrieved oocytes
is not used to select for fertilization nor has it been shown
to predict IVF outcome.
All available oocytes that meet the basic criteria of
mature (MII) undergo standard fertilization by IVF or
ICSI. Embryo characteristics for transfer are based on
morphological characteristics after fertilization which
vary at different institutions.d Central. This is an Open Access article distributed under the terms of the
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Figure 2 Dark ZP oocyte and corresponding Day 3 Embryo.
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intracytoplasmic sperm injection (ICSI) is utilized
there was no decrease in fertilization rates or embryo
quality with ZP abnormalities [3,4]. In addition,
Balaban et al. and had similar findings including no effect
on pregnancy or implantation rates [2]. Balaban et. al used
the following criteria to define oocyte dysmorphology:
1. Extracytoplasmic abnormalities (dark zona pellucida
and large perivitelline space), 2. Cytoplasmic abnormalities
(dark cytoplasm, granular cytoplasm, and refractile body),
3. Shape abnormalities, and 4. Multiple abnormal-
ities (double and triple abnormalities) [2]. However,
Chamayou et al. found a correlation between increased
perivitelline space, presence of granulation and subsequent
embryo quality, but still had no effect on clinical pregnancy
and implantation rate [5]. While most studies have not
documented a negative association of ZP dysmorphology
with decreased IVF outcomes, we noted a predominance
of dysmorphic ZP in the oocytes of several patients
who had poor IVF outcome [6]. We, therefore, designed a
retrospective cohort trial of ZP dysmorphology to assess
its affect on IVF outcome.
Material and methods
Between July 2006 and December 2010, all fresh non-
donor cases preformed at a university hospital IVF
center were assessed for extracytoplasmic abnormalities
oocyte shape: oval or irregularly shaped ZP (Figure 1),
dark ZP (Figure 2) and large perivitelline space (Figure 3)
as defined by Balaban et al. [2]. IRB approval was obtained
for a retrospective study.
136 IVF cycles from 119 subjects under 42 years old
were identified where a majority (over 50% of oocytes)
per cycle displayed one or more extracytoplasmic ZP
abnormality (Figures 1, 2 and 3). Over the same time
a matched control group for age of 77 cycles of 77
subjects in which all the oocyte ZP morphology was
normal were selected as controls. The controls were
carefully matched for age and time period of IVF to
the cases to reduce confounding. One to one matching
was performed for each case of dysmorphic oocyte to aFigure 1 Oval shaped ZP oocyte and embryo.control within 1 year older or 1 year younger in age. All
controls were matched to cases within a week of IVF. In
addition the same experienced embryologist was evaluating
both cases and controls. IVF prognostic and outcome
parameters were compared between the cases and controls
including age, Day 2/3 basal FSH and AMH, as well as total
gonadotropin dose, peak estradiol, oocyte yield, fertilization
rates, blastulation rates, oocyte development (M1 vs. M2),
embryo yield, pregnancy and implantation rates, as well as
live birth rates. There were 15 patients with dysmorphic
oocytes that had more than one cycle. We only included
their last cycle in our analysis. Oocytes were fertilized with
ICSI or conventional IVF based on our standard protocol.
Controlled stimulation during IVF was performed using a
combination of GnRH agonists and gonadotropins, in a
long or short protocol, as well as antagonist protocols for
Figure 3 Enlarged Perivitelline space oocyte and corresponding
day 3 embryo.
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by transvaginal sonography and serial E2 levels. Once oo-
cytes reached 18 mm or more in maximum diameter as
viewed by sonography, 10,000 IU of hCG was administered.
Thirty-five hours after hCG administration, oocytes were
retrieved transvaginally under ultrasound guidance. Insem-
ination was performed approximately 4 hours after retrieval
using either 50,000 motile sperm per oocyte or intracyto-
plasmic sperm injection (ICSI) in the case of male factor
infertility or, occasionally, oocyte factors. Prior to insemin-
ation, the oocytes were viewed under light microscopy and
any abnormal morphology characteristic noted and photo-
graphs taken. Human tubal fluid (HTF) (Irvine Scientific,
Irvine, CA) with 15% synthetic serum substitute (SSS) was
used for embryo culture. The presence of two pronuclei
(2PN) 20 hours after insemination confirmed fertilization.
On day 3 after fertilization the embryos were analyzed for
embryo grade, cell number, and percent fragmentation.
Embryo transfer was performed day 3 vs. day 5 based on
number of fertilized embryos and embryo grading. Serum
beta hCG levels were drawn on days 12 and 14 after trans-
fer. Clinical pregnancy was determined by the presence of a
gestational sac by transvaginal sonography 19 or 20 days
after transfer. Biochemical, nonclinical pregnancies wereincluded in the statistical analyses as nonpregnancies. Live
birth rates were based on SART registry.
Statistical analysis
Descriptive statistics of mean and standard deviation
were computed for continuous patient outcome mea-
sures and compared between patient groups with dys-
morphic and normal oocytes using a student’s t-test.
Blastulation, fertilization, implantation and live birth
rates were computed and corresponding Incidence Rate
Ratios (ratios of rates for dysmorphic to normal) were
estimated and tested for difference from one using Pois-
son regression models. Clinical pregnancy, live birth,
and miscarriage probabilities/proportions were com-
puted and corresponding Relative Risks (ratios of pro-
portions for dysmorphic to normal) were estimated and
tested for difference from one using log binomial
models. Multivariable Poisson and log binomial regres-
sion models were used to estimate age-adjusted relative
risks and incidence rate ratios and ANCOVA was used
to estimate age-adjusted differences in the average num-
ber of embryos transferred and fertilized. Agonist, An-
tagonist and Flare cycle distributions were compared
between dysmorphic and normal oocyte patient groups
using a two sample Chi-Square test. All statistical ana-
lyses were performed using Systat Version 13 and SAS
Version 9.2 (SAS Institute, Inc., Cary, NC). All hypoth-
esis testing was conducted at the 5% level of
significance.
Results
136/1710 (8.0%) cycles of fresh non-donor IVF displayed
predominant ZP dysmorphology. Patients with Dys-
morphic ZP and normal oocytes were 1.2 years older on
average, however showed no difference in the oocyte
quality predictors such as FSH and AMH levels or in
percentage of patients with a poor response defined as
less than 5 oocytes obtained at retrieval. There was still
no difference in oocyte quality predictors even when we
adjusted for age (Table 1). In both Tables 1 and 2 we
present age adjusted estimates and because there are no
difference in most of our outcomes we're reporting the
following results as unadjusted estimates. Patients with
dysmorphic ZP and normal oocytes also showed no sig-
nificant difference in their mean (SD) percent of mature
(M2) oocytes retrieved (78.0% (17.9%) vs. 81.3%
(17.9%)). Patients with dysmorphic ZP required signifi-
cantly more gonadotropins, had borderline significant
lower peak estradiol levels, fewer long protocol cycles
and on average produced 2.5 fewer oocytes per cycle
(10.3 (5.4) vs. 12.8 (5.4); p = 0.002).
Patients with dysmorphic ZP produced on average 2.1
fewer embryos (6.4 (3.7) vs. 8.5 (4.0); p < 0.001) with
similar rates of extended embryo culture compared to





Dysmorphic vs. Normal Dysmorphic vs. Normal oocytes4
Diff1/RR2 / IRR 3 [95% CI] Difference1/RR2 / IRR 3 [95% CI]
N = 119 N = 77 P-value P-value
Age 35.5 (3.9) 34.3 (4.1) 1.2 [0.05,2.4]
Mean (SD) P = 0.040
AMH ng/ml 2.5 (2.0) 2.3 (1.5) 0.2 [−0.9, 1.2] −0.1 [−1.2, 0.9]
Mean (SD) P = 0.762 P = 0.795
FSH IU/l 6.0 (2.5) 6.8 (2.3) −0.8 [−1.7, 0.2] −0.8 [−1.7, 0.2]
Mean (SD) P = 0.115 P = 0.120
Total Gonadotropin dose IU 3847.4 (1791.8) 3128.2 (1842.4) 719 [184, 1254] 525 [12, 1038]
Mean (SD) P = 0.009 P = 0.045
Peak Estradiol Pg/ml 2760.6 (1346.4) 3157.4 (1377.6) −396.8 [−802.7, 9.1] −345.5 [−753.8, 62.8]
Mean (SD) P = 0.055 P = 0.097
Oocytes retrieved per cycle 10.3 (5.4) 12.8 (5.4) −2.5 [−4.0, −0.9] −2.2 [−3.7, −0.6]
Mean (SD) P = 0.002 P = 0.007
% M2 oocytes 78.0% (17.9%) 81.3 (17.9%) −3.3% [−8.4%, 1.9%] −3.4% [−8.6%, 1.8%]
Mean (SD) P = 0.214 p = 0.196
Long Agonist cycles 45% 68% 0.005
Short Antagonist cycles 25% 18%
Short Flare cycles 31% 14%
1Difference estimates used to compare means (SD).
2Relative Risk (RR) estimates used to compare probabilities.
3Incidence Rate Ratio (IRR) estimates used to compare rates.
4Age Adjusted estimates.
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also had lower blastulation with equivalent fertilization
rates and on average 0.4 more transferred embryos per
cycle (3.1 (1.2) vs. 2.7 (1.2); p = 0.021). All of our ZP
abnormalities persisted from oocyte to embryo except
for the enlargement of the perivitelline space. Forty-four
percent of patients with ZP dysmorphology had a
clinical pregnancy while 70% of patients with normal
oocytes had a clinical pregnancy. This represents a 38%
reduction in the likelihood of clinical pregnancy in
patients with ZP dysmorphology (RR:0.62 [0.48, 0.80];
p < 0.001). The implantation rate of 0.17 in dysmorphic
patients was significantly lower than the implantation
rate of 0.36 in normal patients. This represents a 52%
reduction in the implantation rate of dysmorphic
patients (IRR: 0.48 [0.34, 0.68]; p < 0.001). Similarly, 29%
of dysmorphic patients experienced a live birth while
52% of normal oocyte patients had a live birth. This rep-
resents a 45% reduction in the likelihood of a live birth
in dysmorphic patients (RR:0.55 [0.39, 0.79]; p = 0.001).
Results are displayed in Tables 1 and 2.
Discussion
ZP dysmorphology is associated with slightly fewer oocytes
and embryos as well as markedly diminished pregnancy
and implantation rates in IVF. Live birth rates were alsoalmost half the amount of normal oocytes. The poorer
outcome appears to be independent of the usual markers
of ovarian reserve, however the dysmorphic oocytes were
more likely to require more gonadotropins in short agonist
and antagonist cycles indicating these patients showed a
poorer response to stimulation.
It is unclear why ZP dysmorphology may impair
oocyte function however one possible theory is that
ZP dymorphology is a marker for poorer oocyte
quality related to endometriosis. Studies have shown
endometriosis patients to have poorer oocyte quality
because of a higher apoptotic incidence, more alterations
of the cell cycle, and a higher incidence of oxidative stress
than patients with any of the other infertility causes (tube,
male, and idiopathic factors) [7,8]. We initially became
interested in oocyte ZP dysmorphology as several patients
with severe endometriosis had misshapen zona pellucida.
An initial published abstract suggested an association
between ZP dysmorphology and endometriosis, but
further work would be required to confirm any causal
link. Another interesting avenue for research would
be to link cytokines associated with endometriosis
with oocyte ZP dysmorphology.
Another theory is that alterations in ZP morphology
may be caused by patterning problems of the glycoprotein
matrix encoded by ZP 1, 2 and 3 genes. Sterility in mice is









N = 119 N = 77 Difference1/RR2 / IRR 3 [95% CI] Difference1/RR2 / IRR 3 [95% CI]
P-value P-value
Transferred embryo per cycle 3.1 (1.2) 2.7 (1.2) 0.4 [0.06, 0.8] 0.25 [−0.07, 0.57]
Mean (SD) P = 0.021 P = 0.128
Embryos fertilized per cycle 6.35 (3.68) 8.47 (3.98) −2.1 [−3.2, −1.0] −1.91 [−3.00, −0.81]
Mean (SD) P < 0.001 P < 0.001
Blastulation rate per cycle .26 .42 IRR = 0.61 [0.51, 0.73] IRR = 0.68 [0.56, 0.82]
blasts/embryos fertilized 202/756 274/652 P < 0.001 P < 0.001
Fertilization rate per cycle .85 .85 IRR = 0.99 [0.90, 1.11] IRR = 1.00 [0.90, 1.11]
fertilized /oocytes inseminated 832/ 891 652/766 P = 0.953 P = 0.935
Implantation rate .17 .36 IRR = 0.48 [0.34, 0.68] IRR = 0.52 [0.37, 0.73]
sacs/embryos transferred 61/354 72/202 P < 0.001 P < 0.001
Clinical Pregnancy rate per cycle 44% 70% RR = 0.62 [0.48, 0.80] RR = 0.64 [0.49, 0.82]
52/119 54/77 P < 0.001 P < 0.001
Live Birth rate per cycle 29% 52% RR = 0.55 [0.39, 0.79] RR = 0.60 [0.42, 0.87]
34/119 40/77 P = 0.001 P = 0.007
Miscarriage rate 35% 26% RR = 1.34 [0.74, 2.40] RR = 1.28 [0.73, 2.25]
18/52 14/54 P = 0.333 P = 0.396
1Difference estimates used to compare means (SD).
2Relative Risk (RR) estimates used to compare probabilities.
3Incidence Rate Ratio (IRR) estimates used to compare rates.
4Age Adjusted estimates.
N: number of patients in each group equivalent to number of cycles.
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problems have been found in patients with ZP1 and ZP3
gene variations [9-12]. In human oocytes two sequence
variations of ZP3 genes were more frequent in oocytes
with abnormal zona in comparison to those with normal
zona [12]. Therefore these morphologic mutations
may be linked to polymorphisms in the ZP gene although
more research needs to be performed to confirm this
association.
In addition the spherical shape of the ZP ensures
maximal contact between blastomeres of embryos.
Therefore, cleaving embryos from ovoid oocytes may have
a reduced chance to express an optimal cell association.
Ebner et al. [13] described ovoid zona favoring generation
of atypical cleavage patterns resulting in delayed compac-
tion and blastocyst formation. This finding may explain
why the dysmorphic oocytes had decreased blastulation
rates in comparison to our control group
Our results are different than those published by
Balaban and Sutter where no differences were noted
in IVF outcomes. This difference may be explained by the
criteria used to evaluate oocyte morphology in the present
study. While Balaban looked at extracytoplasmic and
cytoplasmic abnormalities, our study primarily looked
at extracytoplasmic ZP abnormalities and oocyte shape.Therefore, the differences in our finding may be attributed
to our emphasis on ZP in comparison to cytoplasmic
abnormalities used by Balaban et al. Rienzi et al. also
found that large perivitelline space correlated with lower
reproductive outcomes and developed an oocyte morph-
ology scoring system incorporating large perivitelline
space along with other intracytoplasmic abnormalities into
their scoring system. They found an inverse relationship
between their oocyte morphological scoring system and
pregnancy rates [1,14]. Similar to our study there was a
finding of poorer IVF outcome.
Our findings support that selecting oocytes with no
dysmorphic characteristics may yield improved outcomes
as is currently common practice in many IVF centers.
Furthermore, cycles with dysmorphic oocytes may be
considered less favorable. Oocyte morphology assessment
may be a useful adjunct to later embryo assessment and
may aid in our decision making about how many embryos
to transfer. Most of our abnormal oocytes and controls
were inseminated with ICSI and assisted hatching as over
90% of cycles at this time were being performed by ICSI in
our lab. There was no significant difference in percentage
of assisted hatching or ICSI between the ZP dysmorphic
and the normal group. Future studies are necessary to
evaluate if ICSI affects clinical outcomes for abnormal
Sauerbrun-Cutler et al. Journal of Ovarian Research  (2015) 8:5 Page 6 of 6oocytes in comparison to standard IVF [15]. As ICSI is
more commonly performed in our lab, we were are unable
to answer this question from this study.
One limitation of our study is that as a retrospective
study we cannot confirm a causal link between the
worse IVF outcomes and ZP dysmorphology. However,
we reduced confounding variables by using a control
group of cycles matched in timing and utilizing the same
embryologist for both the dysmorhpic and normal
oocytes. When we matched our cases to controls we
tried to reduce bias by matching oocytes with ZP
abnormalities to normal oocytes by IVF cycles within
one week of each other and by patient age within
2 years (1 year older or 1 year younger). Our results
showed age matched controls that were statistically
younger therefore it is possible that the lower ages
in the control group with normal ZP features may
have contributed to their favorable IVF outcomes in
comparison to the dysmorphic group. However when
we statistically corrected for age there was no difference
in our oocyte quality predictors or implantation and
clinical pregnancy rates. 15 patients in the dysmorphic
oocyte group had more than one cycle and we only
included their last cycle in our analysis in order to reduce
bias because data from the same patient, although from
different cycles are technically not independent. However,
when we included them in our calculation initially the
outcomes were all the same. In future studies we will
look for possible causes of ZP dysmorphology such as
endometriosis, pelvic infection and chronic pelvic pain.
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